Using Dendrimers to Design Multivalent Therapeutic Agents
Using Dendrimers to Design Multivalent Therapeutic Agents
批准号:
9025660
负责人:
Mary J Cloninger
金额:
$6.55万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-06-01 至 2016-08-31
关键词:
AcetylgalactosamineAcquired Immunodeficiency SyndromeAdhesionsAffinityAlzheimer&aposs DiseaseAnimal ModelAntigensArbitrationArchitectureAvidityBindingBiologicalBiological AssayBiological ModelsBiological ProcessBiologyCaenorhabditis elegansCarbohydratesCell AdhesionCell physiologyCellsChemotaxisCollaborationsDendrimersDevelopmentDiabetes MellitusDiseaseEnvironmentEnzyme-Linked Immunosorbent AssayEventExhibitsExposure toFluorescenceFluorescence AnisotropyFundingGalactoseGalactose Binding LectinGalectin 1Galectin 3GenerationsGoalsIndividualInfluenzaInstitutesKineticsLactoseLigandsMalignant NeoplasmsMediatingMediator of activation proteinMetalloproteasesMigration AssayMolecular Sieve ChromatographyN-acetyllactosamineNeoplasm MetastasisPathway interactionsPatternPeptidesPlayProcessProdrugsPropertyProteinsRelative (related person)ResearchRoleStructureSurface Plasmon ResonanceSystemTechniquesTestingTherapeuticTherapeutic AgentsThompson-Friedenreich AntigenToxic effectUniversitiesangiogenesisbasecancer cellcarbohydrate binding proteindesignextracellularin vivolight scatteringmolecular recognitionmouse modelnovelprogramsreceptorresearch studysmall moleculetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overarching goal of this research program is to develop synthetic multivalent frameworks for the discernment and manipulation of biological recognition processes that are important in intercellular interactions. Multivalency plays a critical role in many biological interactions, and the development of synthetic multivalent systems to systematically probe these processes is critical for advancement of the rational development of multivalent therapeutics. Because typical individual receptor/ligand interactions in biology are often weak, augmentation of these interactions using multivalency can enhance functional avidity. Moreover, multivalent interactions can create patterns of ligands that can be used to modulate processes in novel ways, and these architectures of structure cannot be formed by traditional small-molecule therapeutics. The proposed research describes the development of dendrimers as tools to advance the understanding of the requirements for multivalent frameworks that are designed to mediate multivalent cancer cellular recognition processes. Our hypothesis is that carbohydrate functionalized dendrimers can be used to form clusters of galectins and that these galectin/glycodendrimer clusters will effectively arbitrate the intercellular recognition events of cancer cells. We have chosen glycodendrimers as the multivalent frameworks for the proposed studies because of the ease of manipulation of their size (generation) and of their end group functionalization. We have chosen galectins as our target proteins because of their known functions in cancer processes. The three specific aims are as follows. 1) Synthesize new carbohydrate-functionalized dendrimers. 2) Characterize the glycodendrimer/galectin binding interactions. 3) Perform cell based and animal model (C. elegans) assays with glycodendrimers. For specific aim 1, chemoenzymatic syntheses to form N-acetyllactosamine and Thomsen-Friedenriech antigen functionalized dendrimers are proposed. The synthesis of dendrimers bearing peptide substrates for matrix metalloproteases is also proposed. For specific aim 2, characterization of glycodendrimer/galectin aggregates is proposed using fluorescence lifetime waveform, fluorescence anisotropy, size exclusion chromatography-multiangle light scattering, surface plasmon resonance and ELISA experiments. Because of the effect of galectins -1 and -3 on cancer cellular aggregation processes, our goal is to characterize the binding affinity of the glycodendrimer/galectin interactions and the pattern of galectin that is displayed to the cells in the presence of glycodendrimers. For specific aim 3, we will perform angiogenesis and cellular adhesion assays in collaboration with Dr. Avraham Raz of the Karmanos Cancer Institute at Wayne State University. We also propose to perform homotypic cellular aggregation assays, chemotaxis and migration assays, mechanoelastic studies, kinetic studies on release of prodrug mimics, and studies with C. elegans.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation.
乳糖官能化的树枝状聚合物仲裁了半乳糖素3/MUC1介导的癌细胞聚集的相互作用。
DOI:
10.1002/cbic.201402134
发表时间:
2014-09-22
期刊:
Chembiochem : a European journal of chemical biology
影响因子:
--
作者:
[Michel AK, Nangia-Makker P, Raz A, Cloninger MJ]
通讯作者:
Cloninger MJ
EPR and affinity studies of mannose-TEMPO functionalized PAMAM dendrimers.
甘露糖-TEMPO 功能化 PAMAM 树枝状聚合物的 EPR 和亲和力研究。
DOI:
10.1039/b411643g
发表时间:
2004
期刊:
Organic & biomolecular chemistry
影响因子:
3.2
作者:
[Samuelson,LynnE, Sebby,KarlB, Walter,EricD, Singel,DavidJ, Cloninger,MaryJ]
通讯作者:
Cloninger,MaryJ
DOI:
10.1021/jp112390d
发表时间:
2011-04-28
期刊:
JOURNAL OF PHYSICAL CHEMISTRY B
影响因子:
3.3
作者:
[Sebby, Karl B., Walter, Eric D., Usselman, Robert J., Cloninger, Mary J., Singel, David J.]
通讯作者:
Singel, David J.
DOI:
10.3762/bjoc.10.162
发表时间:
2014
期刊:
Beilstein journal of organic chemistry
影响因子:
2.7
作者:
[Goodman CK, Wolfenden ML, Nangia-Makker P, Michel AK, Raz A, Cloninger MJ]
通讯作者:
Cloninger MJ
DOI:
10.1021/acs.biomac.1c01001
发表时间:
2021-11-08
期刊:
Biomacromolecules
影响因子:
6.2
作者:
[VanKoten HW, Moore RS, Cloninger MJ]
通讯作者:
Cloninger MJ
共 17 条
Symposium funding request for "Multivalent Drug Design"
-
批准号:8130402
-
项目类别:
-
资助金额:$0.25万
-
财政年份:2011
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:7939520
-
项目类别:
-
资助金额:$4.19万
-
财政年份:2009
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:7883730
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:8236550
-
项目类别:
-
资助金额:$30.21万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:6400401
-
项目类别:
-
资助金额:$21.39万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:6899794
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:8720009
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:7535503
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:8916768
-
项目类别:
-
资助金额:$30.21万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:7196345
-
项目类别:
-
资助金额:$6.81万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:8537470
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:6748494
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:6636562
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agent
-
批准号:6520391
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2001
-
负责人:Mary J Cloninger
-
依托单位:
Using Dendrimers to Design Multivalent Therapeutic Agents
-
批准号:7201830
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2000
-
负责人:Mary J Cloninger
-
依托单位:
海外基金